ORIGINAL RESEARCH article
Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1493436
On the op mal frac ona on scheme for lymphocyte infiltra on in GBM radiotherapy treatment
Provisionally accepted
- INSERM U1021 Signalisation Normale et Pathologique de l'embryon aux Thérapies Innovantes des Cancers, Orsay, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Some radioresistant and immunosuppressive tumors, such as glioblastoma mul forme (GBM), are s ll a challenge and current clinical prac ce, surgical resec on and chemoradia on, do not yet offer effec ve treatments. Immunotherapy (IT) has emerged as a powerful tool in the arsenal against cancer. IT was also explored in GBM phase III clinical trials, with unsuccessful results since it is cri cally dependent on the availability of preexis ng an -tumor immunity. Given its immunomodulatory poten al, RT could be employed as a tool to inflame tumors for increasing their response to IT. The radia on configura on to achieve the cri cal tumor inflamma on needed for IT success remains elusive. In this study the op mum dose frac ona on scheme to maximize immune cell tumor infiltra on was assessed.Two orthotopic rat glioma models, having different vasculariza on and immunogenicity levels, were irradiated with three different dose frac ona on schemes. Tumor immune cell popula ons were assessed by flow cytometry.One single high dose (25 Gy) or extreme hypofrac ona on is needed to elicit a significant immune infiltra on in the tumors.
Keywords: Radiotherapy, Glioma, Lymphocytes, Infiltration, Fractionation
Received: 09 Sep 2024; Accepted: 10 Mar 2025.
Copyright: © 2025 Iturri, Juchaux, Gilbert, espenon and Prezado. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yolanda Prezado, INSERM U1021 Signalisation Normale et Pathologique de l'embryon aux Thérapies Innovantes des Cancers, Orsay, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.